Author: Jim Peacock

ProteinLogic, the biomarker discovery and exploitation company, has appointed Dr Roslin Russell as Vice President of Bioinformatics & Computational Biology to bring technical expertise in the execution of the company’s R&D strategy. Before joining ProteinLogic, Roslin Russell spent eight years working for the Cambridge Institute, Cancer Research UK, as a computational biologist specialising in high-throughput data analysis: microarray, next generation sequencing and protein mass-spectrometry. With eighteen years’ experience in bioinformatics and computational biology she’s also been hands-on with wet-lab experiments and her research areas include parasitlogy and infectious diseases, immunology as well as oncology. Roslin will use her capabilities to…

ProteinLogic, the biomarker discovery and exploitation company, has appointed Mr Damon Parkington as Assay Development and Research Scientist to provide technical leadership in the development of novel immunoassays for research and to bring expertise on relevant clinical instruments to further the company’s R&D and business development strategies. Damon Parkingon is an HCPC-registered Biomedical Scientist with a Clinical Biochemistry background. He has gained experience in a wide range of laboratory techniques whilst working in NHS Blood Sciences laboratories. His specialty is immunoassay development and he has extensive experience in this, having developed immunoassays using both manual and automated instruments. Damon is…

ProteinLogic, the biomarker discovery and exploitation company, has appointed Mr Mahesh Shah (MBA) as Executive Chairman to lead the business as it expands into the TB diagnostics space. Mahesh Shah was the founder and CEO of the retail pharmacy business Nucare PLC, a company with operations in the UK as well as overseas. Under his stewardship the business grew both organically and through joint ventures and acquisitions, and he led a successful trade sale in 2007, realising an enterprise value of approximately £70 million. Mr Shah has professional qualifications in pharmacy, accounting, finance and business, and has extensive practical expertise…

A European Consortium of leading academic and clinical partners, including ProteinLogic, a UK based biomarker discovery company, have been awarded a grant by the European Union Horizon 2020 SME program to help harness the diagnostic power of genome sequencing in day-to-day clinical practice. ProteinLogic are pleased to announce they have been awarded €415,000 by the European Commission, for the development of a new cancer diagnostic test, comprising both genomic and proteomic biomarkers. The funding was awarded as a result of a successful €2.95 million grant application in partnership with five other European Clinical and Academic Collaborators. The ability to sequence…

ProteinLogic, a biomarker discovery company, and its collaborator, Biosensia, an in vitro diagnostic company have been awarded a grant by the European Union Horizon 2020 SME programme to develop a rapid point-of-care test for the diagnosis of Active Tuberculosis (TB). Almost 9m new cases of TB occur annually and there are over 1.4m deaths every year despite most cases being curable. More than 3m people contracting TB each year go undiagnosed and untreated according to the World Health Organisation. WHO is now calling for accelerated uptake of new tools and strategies for better diagnosis, treatment and prevention of all forms…

CAMBRIDGE, UK (2013-11-12) – ProteinLogic, a biomarker discovery and exploitation company, Microtest Diagnostics, an in vitro diagnostic protein multiplexing company, and its collaborators have been awarded a grant by the government-backed Technology Strategy Board – the UK’s national innovation agency – to help support the development of MICROLOGIC™, a rapid point-of-care test for tuberculosis (TB). Almost 9m new cases of TB occur annually and there are over 1m deaths every year despite most cases being curable. More than 3m people contracting TB each year go undiagnosed and untreated according to the World Health Organisation. WHO is now calling for accelerated…

CAMBRIDGE, UK (2013-06-21) – ProteinLogic, the biomarker discovery and exploitation company, has appointed Dr Aron Rachamim as Chief Operating Officer (COO) to provide technical and business leadership in the execution of the company’s R&D and business development strategies. Aron graduated from the University of Oxford with an MPhys in Physics, following which he obtained an MPhil in Micro- & Nanotechnology Enterprise from the University of Cambridge. He then stayed on at Cambridge to study for a PhD in Engineering working on biosensors. Prior to joining ProteinLogic he founded a university spin-out company and practised as an independent management consultant. His…

CAMBRIDGE, UK (2013-03-25) – ProteinLogic, the biomarker discovery and exploitation company, was judged to have presented the strongest proposal in the Med Tech category to the Innovators’ Den at the NHS Healthcare Innovation Expo 2013 in London on March 14th. ProteinLogic’s Chairman Dr Paul Rodgers presented the winning pitch to a panel including leading venture capitalists and senior NHS decision makers in front of a live audience. He outlined the ProteinLogic technology and its progress in implementing a business strategy to commercialise biomarker-based diagnostic tests for a range of diseases including tuberculosis and hepatitis B. Eighty companies entered the competition…

CAMBRIDGE, UK (2013-02-18) – ProteinLogic awarded Technology Strategy Board funding to support its research into a novel diagnostic test for tuberculosis ProteinLogic, the biomarker discovery and exploitation company, has been awarded a grant by the Technology Strategy Board – the UK’s national innovation agency – to help support the development of a new diagnostic test for tuberculosis (TB). ProteinLogic has identified a panel of biomarker proteins that has the potential to form the basis of a simple diagnostic blood test to differentiate between patients with active and latent TB infections. The Technology Strategy Board funding, awarded through the Biomedical Catalyst…

CAMBRIDGE, UK (2012-09-03) – ProteinLogic, the biomarker discovery and exploitation company, has been awarded a grant by the Technology Strategy Board – the UK’s national innovation agency – to help support the development of a new Diagnostic Test for Hepatitis B. ProteinLogic has identified a panel of biomarker proteins that has the potential to form the basis of a simple diagnostic blood test to stratify patients with chronic hepatitis B infection. The Technology Strategy Board funding will enable ProteinLogic to undertake market research to establish whether there is a commercially viable market opportunity and to carry out a small clinical…